Nautilus Biotechnology Inc

NASDAQ NAUT

Data sourced from

and

Daily

Download Data

Nautilus Biotechnology Inc Market Capitalization on June 03, 2024: USD 339.47 M

Nautilus Biotechnology Inc Market Capitalization is USD 339.47 M on June 03, 2024, a -0.22% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Nautilus Biotechnology Inc 52-week high Market Capitalization is USD 563.26 M on June 20, 2023, which is 65.92% above the current Market Capitalization.
Nautilus Biotechnology Inc 52-week low Market Capitalization is USD 294.88 K on April 25, 2024, which is -99.91% below the current Market Capitalization.
Nautilus Biotechnology Inc average Market Capitalization for the last 52 weeks is USD 367.66 M.

NASDAQ: NAUT

Nautilus Biotechnology Inc

CEO	Mr. Sujal M. Patel
IPO Date	June 10, 2021
Location	United States
Headquarters	2701 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	163
Sector	Healthcare
Industry	Biotechnology

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Key trends